Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
Supply continues to cause headaches for radiopharmaceutical developers.
But will the FDA accept the surrogate endpoint used in ASC4First?
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.